There are nearly 100 treatments being tested in clinical trials around the US for myeloma patients. It can be a confusing and difficult task to find a trial or treatment that may be right for you. Below is a list of featured treatments to help you get started. If you have questions, you can call us or create an account today and we'll help you better understand your clinical trial options.
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST
Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
RO6870810 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called Bromodomain and Extra-Terminal Protein (BET) Inhibitors.
Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated in a Phase I clinical trial in patients with relapsed or refractory multiple myeloma. Based upon pre-clinical and interim Phase I study data, treatment with CLR 131 provides patients with a novel approach to treating hematological diseases and may provide patients with an improvement in progression-free survival and overall quality of life. CLR 131 utilizes the company’s patented PDC tumor targeting delivery platform to deliver a cytotoxic radioisotope, iodine-131 directly to tumor cells. The FDA has granted Cellectar an orphan drug designation for CLR 131.
Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
Antibodies are cloned and used to attack one specific type of protein found in cancer cells.
Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
A bispecific antibody is a drug that has been designed to simultaneously target two different antigens. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells. This approach gives additional options in targeted immunotherapy and may help the immune system find and kill the cancer cells.